Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

被引：4
|
作者：
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8028
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Weisel, Katja
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth Carl
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna Ellen
    Beksac, Meral
    Shelat, Suresh
    Sy, Oumar
    Singhal, Anil K.
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Dimopoulos, Meletios
    Weisel, Katja
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San Miguel, Jesus
    Anderson, Kenneth
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Shelat, Suresh
    Sy, Oumar
    Singhal, Anil
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S253 - S253
  • [3] Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 35 - 35
  • [4] PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [5] Phase 3 ELOQUENT-2 study extended 5-y follow-up comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with Ld to treat relapsed/refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M-, V
    San Miguel, J.
    Anderson, K.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I
    Walter-Cronek, A.
    Magen, H.
    Belch, A.
    Reece, D.
    Beksac, M.
    Shelat, S. G.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 230 - 230
  • [6] ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M. -V
    Belch, A.
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A. K.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 123
  • [7] ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomidefdexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)-Identifying responders by subset analysis.
    Lonial, Sagar
    Richardson, Paul G.
    Mateos, Maria-Victoria
    Weisel, Katja
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Sy, Oumar
    Katz, Jessica
    Gupta, Manish
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] ELOQUENT-2: Extended safety and efficacy follow-up of the phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M.
    Lonial, S.
    White, D.
    Moreau, P.
    Palumbo, A.
    San Miguel, J.
    Shpilberg, O.
    Anderson, K.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen-Nativ, H.
    Mateos, M-V
    Reece, D.
    Beksac, M.
    Bleickardt, E.
    Poulart, V.
    Katz, J.
    Singhal, A.
    Richardson, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 6 - 7
  • [9] Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
    Dimopoulos, Meletios A.
    Weisel, Katja
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Mateos, Maria-Victoria
    San-Miguel, Jesus
    Anderson, Kenneth C.
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Ganetsky, Alex
    Jou, Ying-Ming
    McKiver, Mihaela Popa
    Singhal, Anil K.
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E15 - E16
  • [10] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Betts, Keith A.
    Chen, Clara
    Zichlin, Miriam L.
    Brun, Alexander
    Signorovitch, James E.
    Makenbaeva, Dinara
    Mekan, Sabeen
    Sy, Oumar
    Weisel, Katja
    Richardson, Paul G.
    CANCER, 2018, 124 (20) : 4032 - 4043
12345